We are live on ! Find out more
VVOS icon

Vivos Therapeutics
VVOS

10 hedge funds and large institutions have $3.88M invested in Vivos Therapeutics in 2020 Q4 according to their latest regulatory filings, with 10 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0.17% more ownership

Funds ownership: 0% → 0.17% (+0.17%)

Holders
10
Holders Change
+10
Holders Change %
–
% of All Funds
0.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RA
Royce & Associates
New York
+$2.19M
2
KJHP
K.J. Harrison & Partners
Ontario, Canada
+$667K
3
Millennium Management
Millennium Management
New York
+$609K
4
Walleye Capital
Walleye Capital
New York
+$544K
5
KPF
K2 Principal Fund
Ontario, Canada
+$375K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
RA
1
Royce & Associates
New York
$1.77M +$2.19M +12,000 New
KJHP
2
K.J. Harrison & Partners
Ontario, Canada
$540K +$667K +3,653 New
Millennium Management
3
Millennium Management
New York
$493K +$609K +3,337 New
KPF
4
K2 Principal Fund
Ontario, Canada
$304K +$375K +2,056 New
MA
5
MYDA Advisors
New York
$260K +$321K +1,760 New
MS
6
Maven Securities
Jersey
$197K +$234K +1,280 New
Jane Street
7
Jane Street
New York
$191K +$235K +1,289 New
PCM
8
Perkins Capital Management
Minnesota
$118K +$146K +800 New
Morgan Stanley
9
Morgan Stanley
New York
$6K +$7.3K +40 New
Walleye Capital
10
Walleye Capital
New York
$440 +$544K +2,980 New

VVOS Hedge Fund Activity: Q4 2020 in Review

10 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Vivos Therapeutics (VVOS) for Q4 2020, worth a combined $3.88M.

Buyers outnumbered sellers: 10 funds opened new VVOS positions and 0 closed out — a net gain of 10 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Royce & Associates, opening a new position worth an estimated $2.19M.

  • 10 institutional investors held Vivos Therapeutics (VVOS) as of Q4 2020, up from 0 in Q3 2020.
  • Funds reported $3.88M of Vivos Therapeutics stock for Q4 2020.
  • 10 funds opened new Vivos Therapeutics positions in Q4 2020 and 0 closed out, a net change of +10 holders.
  • The largest Vivos Therapeutics buyer in Q4 2020 was Royce & Associates, an estimated $2.19M added.

Based on aggregated 13F filings for Q4 2020.